Bial-portela Ca & S.a.

Bial-Portela & Cª, S.a.

William Maton

Jorge Bruno Reis Wahnon

Domenico Russo

Laszlo Erno Kiss

Patricio Manuel Vieira Araujo Soares Da Silva

Carla Patricia Da Costa Pereira Rosa

Rita Gusmao De Noronha

David Alexander Learmonth

Alexander Beliaev

Jean-Marie Schneider

Jonathan Madec

Beat Theodor Weber

Patrício Manuel Vieira Araújo Soares Da Silva

Tibor Eszenyi

Paula Jeronimo

Teofilo Vasconcelos

Ricardo Lima

Rita Pires

Pedro Barrocas

Luisa Sousa

Jorge Wahnon

Paula JERÓNIMO

Teófilo Vasconcelos

Luísa Sousa

Rita GUSMÃO De Noronha

The present invention concerns a process for preparing a compound having the Formula A; or a pharmaceutically acceptable salt or derivative thereof, or for preparing a substituted urea compound of Formula IIa, or a pharmaceutically acceptable salt or ester thereof, the process comprising the reaction of an imidazolyl intermediate of Formula IIa' with a carbamoyl halide of the formula: R1R2NC(&#x2550;O)Hal, wherein Hal represents Cl, F, I or Br, wherein the intermediate of Formula IIa&#x2032; is prepared by oxidation of the derivative of R5 and R6, R6-C(&#x2550;O)CHR5 to form a glyoxal intermediate R6-C(&#x2550;O)(C&#x2550;O)R5, which is subjected to treatment with ammonium hydroxide and an aldehyde R8CHO to provide the intermediate of Formula IIa&#x2032; and wherein the compound substituents are as defined herein. 

Processes for the synthesis of substituted urea compounds

A compound having the following structure: or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.

Urea compounds and their use as enzyme inhibitors

The present invention provides a compound of formula N wherein: X is CH, oxygen or sulphur; R, Rand Rare the same or different and signify hydrogens, halogens, alkyl, alkyloxy, hydroxy, nitro, alkylcarbonylamino, alkylamino or dialkylamino group, wherein N is in the form of the individual R- and S-enantiomer or a mixture of the (R)- and (S)-enantiomer. The present invention also provides a compound of formula MA. The present invention also provides processes for preparing the above compounds, and processes involving their use. The compounds are particularly useful as intermediates in the synthesis of peripherally-selective inhibitors of dopamine-&#x3b2;-hydroxylase. 

Processes for preparing medicaments for the treatment of cardiovascular diseases and intermediates for use therein

The present invention relates to a process for preparing (R)-5-(2-(benzylamino)ethyl)-1-(6,8-difluorochroman-3-yl)-1H-imidazole-2(3H)-thione, and pharmaceutically acceptable salts thereof, especially the hydrochloride salt. The invention also relates to a process for making intermediates useful in the formation of said compound, and to the intermediates, per se.

Process for preparing 1,3-dihydroimidazole-2-thione derivatives

Process for preparing 1, 3-Dihydroimidazole-2-Thione Derivatives

Growing community of inventors

S. Mamede do Coronado, Portugal

William Maton